<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03124108</url>
  </required_header>
  <id_info>
    <org_study_id>GFT505B-216-1</org_study_id>
    <secondary_id>2016-003817-80</secondary_id>
    <nct_id>NCT03124108</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Elafibranor at Doses of 80 mg and 120mg After 12 Weeks of Treatment in Patients With Primary Biliary Cholangitis and Inadequate Response to Ursodeoxycholic Acid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genfit</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genfit</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to compare the effect of daily oral administration of
      elafibranor 80mg and 120 mg on change in serum alkaline phosphatase (ALP) to that of placebo
      in patients with PBC and inadequate response to Ursodeoxycholic acid (UDCA).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 5, 2017</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in serum alkaline phosphatase (ALP)</measure>
    <time_frame>Measurements at Baseline and 12 weeks</time_frame>
    <description>To evaluate the efficacy of elafibranor 80 and 120 mg with respect to relative change from baseline in serum ALP levels compared to placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite endpoint composed of ALP and total bilirubin</measure>
    <time_frame>Measurements at 12 weeks</time_frame>
    <description>To assess response rate in elafibranor 80 mg and 120 mg and placebo groups, with response defined as ALP less than 1.67 times ULN and total bilirubin within normal limits and ALP reduction &gt; 15%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite endpoint composed of ALP and total bilirubin</measure>
    <time_frame>Measurements at 12 weeks</time_frame>
    <description>To assess response rate in elafibranor 80 mg and 120 mg and placebo groups, with response defined as ALP less than 2 times ULN and total bilirubin within normal limits and ALP reduction &gt; 40%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Paris I PBC risk score</measure>
    <time_frame>Measurements at 12 weeks</time_frame>
    <description>To assess response rate in elafibranor 80 mg and 120 mg and placebo groups according to Paris I PBC risk score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Paris II PBC risk score</measure>
    <time_frame>Measurements at 12 weeks</time_frame>
    <description>To assess response rate in elafibranor 80 mg and 120 mg and placebo groups according to Paris II PBC risk score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toronto I PBC risk score</measure>
    <time_frame>Measurements at 12 weeks</time_frame>
    <description>To assess response rate in elafibranor 80 mg and 120 mg and placebo groups according to Toronto I PBC risk score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toronto II PBC risk score</measure>
    <time_frame>Measurements at 12 weeks</time_frame>
    <description>To assess response rate in elafibranor 80 mg and 120 mg and placebo groups according to Toronto II PBC risk score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UK PBC risk score</measure>
    <time_frame>Measurements at 12 weeks</time_frame>
    <description>To assess response rate in elafibranor 80 mg and 120 mg and placebo groups according to UK PBC risk score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalization of ALP levels</measure>
    <time_frame>Measurements at 12 weeks</time_frame>
    <description>To assess the response to elafibranor 80 mg and 120 mg versus placebo treatment on normalization of ALP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver enzymes</measure>
    <time_frame>Measurements at Baseline and 12 weeks</time_frame>
    <description>To assess the response to elafibranor 80 mg and 120 mg versus placebo treatment on liver enzymes and liver markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrosis markers</measure>
    <time_frame>Measurements at Baseline and 12 weeks</time_frame>
    <description>To assess the response to elafibranor 80 mg and 120 mg versus placebo treatment on fibrosis markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid parameters</measure>
    <time_frame>Measurements at Baseline and 12 weeks</time_frame>
    <description>To assess the response to elafibranor 80 mg and 120 mg versus placebo treatment on lipid parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>Measurements at Baseline and 12 weeks</time_frame>
    <description>To assess the response to elafibranor 80 mg and 120 mg versus placebo treatment on inflammatory markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pruritis score</measure>
    <time_frame>Measurements at Baseline and 12 weeks</time_frame>
    <description>To assess the efficacy of elafibranor 80 and 120 mg versus placebo treatment with respect to the change from baseline in pruritus (through 5D-itch scale and visual analogue score VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life parameters</measure>
    <time_frame>Measurements at Baseline and 12 weeks</time_frame>
    <description>To assess the efficacy of elafibranor 80 and 120 mg versus placebo treatment with respect to the change from baseline in Quality of Life (using PBC 40 questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the tolerability and safety of elafibranor 80 mg and 120 mg in patients with PBC</measure>
    <time_frame>12 weeks</time_frame>
    <description>To monitor adverse events</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Primary Biliary Cholangitis (PBC)</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Study subjects will take two tablets per day orally before breakfast with a glass of water each morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elafibranor 80 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study subjects will take two tablets per day orally before breakfast with a glass of water each morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elafibranor 120 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study subjects will take two tablets per day orally before breakfast with a glass of water each morning</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elafibranor 80 mg</intervention_name>
    <description>Two coated tablets daily for 12 weeks</description>
    <arm_group_label>Elafibranor 80 mg</arm_group_label>
    <other_name>GFT505</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elafibranor 120 mg</intervention_name>
    <description>Two coated tablets daily for 12 weeks</description>
    <arm_group_label>Elafibranor 120 mg</arm_group_label>
    <other_name>GFT505</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Two coated tablets daily for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Must have provided written informed consent

          2. Definite or probable PBC diagnosis as demonstrated by the presence of at least 2 of
             the following 3 diagnostic factors:

               -  History of elevated ALP levels for at least 6 months prior to Day 0
                  (randomization visit)

               -  Positive Anti-Mitochondrial Antibodies (AMA) titers (&gt; 1/40 on immunofluorescence
                  or M2 positive by enzyme-linked immunosorbent assay (ELISA) or positive
                  PBC-specific antinuclear antibodies

               -  Liver biopsy consistent with PBC

          3. ALP ≥ 1.67x upper limit of normal (ULN)

          4. Taking UDCA for at least 12 months (stable dose for ≥ 6 months) prior to screening
             visit

          5. Contraception: Females participating in this study must be of non-childbearing
             potential or must be using highly efficient contraception for the full duration of the
             study and for 1 month after the end of treatment.

        Exclusion Criteria:

          1. History or presence of other concomitant liver diseases

          2. Screening CPK &gt; ULN

          3. Screening ALT or AST &gt; 5 ULN

          4. Screening total bilirubin &gt; 2 ULN

          5. Screening serum creatinine &gt; 1.5 mg/dl

          6. Significant renal disease, including nephritic syndrome, chronic kidney disease
             (defined as patients with markers of kidney damage or estimated glomerular filtration
             rate [eGFR] of less than 60 mL/min/1.73 m2).

          7. Patients with moderate or severe hepatic impairment (defined as Child-Pugh B/C)

          8. Platelet count &lt;150 X 10 3/microliter

          9. Albumin &lt;3.5 g/dL

         10. Presence of clinical complications of PBC or clinically significant hepatic
             decompensation

         11. If female: known pregnancy, or has a positive urine pregnancy test (confirmed by a
             positive serum pregnancy test), or lactating

         12. Known history of human immunodeficiency virus (HIV) infection

         13. Medical conditions that may cause non-hepatic increases in ALP (e.g., Paget's disease)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sophie Megnien, MD</last_name>
    <role>Study Director</role>
    <affiliation>Chief Medical Officer, Genfit</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sophie Megnien, MD</last_name>
    <phone>+33 320 164 000</phone>
    <email>sophie.megnien@genfit.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Charleen Pagel Jue, B.S., R.N.</last_name>
    <phone>+33 320 164 000</phone>
    <email>charleen.pageljue@genfit.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth J. Carey, MD</last_name>
      <phone>480-342-2000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Schiff Center for Liver Diseases</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia Levy, MD</last_name>
      <phone>305-243-4615</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Pratt, MD</last_name>
      <phone>617-724-3836</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan Bonder, MD</last_name>
      <phone>617-632-1086</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwell Health - Sandra Atlas Bass Center for Liver Disease</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henry C. Bodenheimer, MD</last_name>
      <phone>516-562-4664</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marlyn Mayo, MD</last_name>
      <phone>214-648-2725</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine - Advanced Liver Therapies</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John M. Vierling, MD</last_name>
      <phone>832-355-8966</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen H. Caldwell, MD</last_name>
      <phone>434-924-2626</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Velimir Luketic, MD</last_name>
      <phone>804-828-4060</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Swedish Organ Transplant and Liver Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kris Kowdley, MD</last_name>
      <phone>206-386-3880</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinic for Gastroenterology and Hepatology</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Münevver Demir, MD</last_name>
      <phone>+49 (0)2214 787334</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johannes Gutenberg University</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorn M Schattenberg, MD</last_name>
      <phone>+49 (0)6131 176831</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adolfo Gallego Moya, MD</last_name>
      <phone>+34 932 919-000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liver Unit, University of Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert Pares, MD</last_name>
      <phone>+34 932 275-753</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2GW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gideon Hirschfield, MD</last_name>
      <phone>+44 (0)121 415-8700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Mells, MD</last_name>
      <phone>+44 (0)122 324-5151</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Royal Liverpool University Hospital</name>
      <address>
        <city>Liverpool</city>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Imran Patanwala, MD</last_name>
      <phone>+44 (0)151 706-2000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Free London NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Douglas Thorburn, MD</last_name>
      <phone>+44 (0)207 794-0500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Liver Studies, King's College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Heneghan, MD</last_name>
      <phone>+44 (0)203 299-7615</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Infirmary</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Jones, MD</last_name>
      <phone>+44 (0)191 222-8335</phone>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2017</study_first_submitted>
  <study_first_submitted_qc>April 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2017</study_first_posted>
  <last_update_submitted>February 20, 2018</last_update_submitted>
  <last_update_submitted_qc>February 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Elafibranor</keyword>
  <keyword>Primary Biliary Cholangitis</keyword>
  <keyword>Alkaline phosphatase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ursodeoxycholic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

